How to Get Vyleesi in Illinois

What Is Vyleesi and Why Does It Require a Prescription?

Bremelanotide (Vyleesi) is a melanocortin receptor agonist approved by the FDA in June 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not a hormone and does not work like flibanserin (Addyi). Bremelanotide activates MC1R and MC4R receptors in the central nervous system to modulate sexual desire pathways, producing measurable increases in satisfying sexual events and reductions in distress related to low desire.

Because the drug carries warnings for transient blood-pressure changes and nausea, federal law classifies it as Schedule V exempt but still requires a valid prescription. The FDA label specifies that it should not be used in patients with cardiovascular disease or uncontrolled hypertension. [1]

The RECONNECT Trial: What the Evidence Actually Shows

The RECONNECT program consisted of two replicate Phase 3 randomized controlled trials (published together in Obstetrics and Gynecology, 2019, N=1,247 combined). Women receiving bremelanotide 1.75 mg showed a statistically significant improvement on the Female Sexual Function Index desire domain score compared to placebo (P<0.001), alongside a significant reduction on the Female Sexual Distress Scale-Desire/Arousal/Orgasm total score. [2]

Specifically, 25% of bremelanotide-treated women reported a meaningful improvement in desire versus 17% on placebo, and 35% reported a meaningful reduction in distress versus 25% on placebo. Nausea occurred in 40% of treated patients but was mostly mild-to-moderate and transient, resolving within 12 hours. [2]

FDA Approval Scope and Off-Label Boundaries

The FDA approval covers only premenopausal women with acquired, generalized HSDD. "Acquired" means HSDD that was not lifelong; "generalized" means it occurs regardless of partner, situation, or type of stimulation. Prescribing outside these parameters is considered off-label use and may complicate insurance coverage in Illinois.

The American College of Obstetricians and Gynecologists (ACOG) acknowledges HSDD as a clinically significant condition affecting an estimated 8% to 12% of U.S. Women of reproductive age. [3]

Who Can Prescribe Vyleesi in Illinois?

Illinois law does not restrict bremelanotide prescribing to a single specialty. Any licensed prescriber with authority to write Schedule V or non-scheduled legend drugs may issue a Vyleesi prescription, provided a valid patient-provider relationship has been established.

Physician (MD/DO)

Board-certified gynecologists, internists, psychiatrists, and family medicine physicians in Illinois may all prescribe Vyleesi. Gynecologists and sexual medicine specialists are most familiar with the FSFI scoring tools used to document HSDD. The Illinois Department of Financial and Professional Regulation (IDFPR) licenses these providers and maintains public verification. [4]

Nurse Practitioners and Physician Assistants

Illinois NPs with full practice authority and PAs operating under a supervision agreement with a physician may prescribe bremelanotide. The Illinois Nurse Practice Act (225 ILCS 65/) grants prescriptive authority to advanced practice registered nurses who hold a controlled substance license, and bremelanotide falls within that scope. [5]

Telehealth Providers

Illinois adopted comprehensive telehealth parity under Public Act 101-0528, which requires insurers to cover telehealth services at parity with in-person care. [6] A licensed Illinois telehealth provider may conduct the intake evaluation, review cardiovascular history, and issue a Vyleesi prescription electronically without an in-person visit, provided the provider holds an active Illinois license and the patient is physically located in Illinois at the time of the visit.

Labs and Clinical Evaluation Required Before Vyleesi

A pre-prescription workup for bremelanotide is straightforward compared to most hormone therapies. The FDA label does not mandate a specific lab panel, but clinical practice guidelines and prescriber liability standards call for the following. [1]

Cardiovascular Baseline

The FDA label for Vyleesi warns that the drug produces a transient mean maximum increase in systolic blood pressure of approximately 6 mmHg and a mean maximum decrease in heart rate of approximately 4 bpm, peaking around 4 hours post-dose and resolving within 12 hours. [1] Because of this, a resting blood pressure measurement is required before the first prescription. Patients with resting systolic blood pressure above 135 mmHg or diastolic above 85 mmHg at baseline should be treated with caution.

Pregnancy Status and Contraception Review

Vyleesi is contraindicated in pregnancy. A urine or serum hCG test is standard before initiation. The FDA label also recommends discussing reliable contraception because bremelanotide may transiently increase blood pressure, which adds risk in unrecognized pregnancy. [1]

Psychological and Diagnostic Screening

HSDD diagnosis under DSM-5 criteria requires that low desire causes marked distress or interpersonal difficulty and is not better explained by another mental disorder, relationship distress, substance use, or another medical condition. [7] Most prescribers use the validated Female Sexual Distress Scale-Revised (FSDS-R) or the FSFI to document diagnostic criteria before prescribing. Online consultations typically send these questionnaires as secure intake forms before the appointment.

Liver and Renal Function (Situational)

The Vyleesi label notes that no dose adjustment is required for mild hepatic or renal impairment, but it has not been studied in severe impairment. [1] Prescribers evaluating patients with known hepatic or renal disease will typically order a basic metabolic panel (BMP) and liver function tests (LFTs) before proceeding.

How to Get a Vyleesi Prescription in Illinois: Step-by-Step

Getting a Vyleesi prescription in Illinois follows a clear sequence regardless of whether you see a provider in person or via telehealth.

Step 1: Choose a Provider

Search the IDFPR license lookup for a gynecologist or sexual medicine specialist in Illinois. [4] Alternatively, select an Illinois-licensed telehealth platform. Confirm the provider holds an active Illinois license and accepts new patients for HSDD evaluation. HealthRX connects patients in Illinois with board-certified clinicians who specialize in sexual health.

Step 2: Complete the Intake Questionnaire

Before your appointment, you will typically complete the FSFI or FSDS-R questionnaire electronically. These validated tools quantify desire impairment and distress, which the provider uses both for diagnosis and for prior authorization documentation. The FSFI has a desire subdomain score where a value of 3.3 or below out of 6.0 indicates clinically meaningful impairment. [8]

Step 3: Attend the Telehealth or In-Person Visit

A bremelanotide consultation typically runs 20 to 35 minutes. The provider will review your sexual and reproductive health history, cardiovascular history, current medications (particularly those that raise blood pressure), and rule out secondary causes of low desire such as hypothyroidism, depression, or relationship-related distress. Blood pressure may be taken in clinic or self-reported for telehealth (a home blood pressure cuff reading taken within 24 hours is generally accepted).

Step 4: Receive the Prescription and Initiate Prior Authorization if Needed

If you have commercial insurance, confirm your formulary before the appointment. If Vyleesi is not listed on your plan's formulary, your provider will initiate a prior authorization (PA). Illinois Medicaid (Medicaid Managed Care and FFS) covers bremelanotide with PA. For prior authorization, the prescribing clinician typically submits the completed FSFI/FSDS-R scores, DSM-5 documentation, and evidence that relationship or psychological causes have been excluded or addressed. [9]

Step 5: Pharmacy Dispensing or 503A Compounding

A standard Vyleesi auto-injector (1.75 mg/0.4 mL) is dispensed by specialty or retail pharmacies in Illinois. Several national specialty pharmacies ship to Illinois addresses within 2 to 5 business days. Illinois-licensed 503A compounding pharmacies may also prepare bremelanotide 1.75 mg subcutaneous injections when a commercially available product is not accessible or when a patient requires a modified formulation per the prescriber's order. [10]

Illinois Medicaid and Commercial Insurance Coverage

Medicaid Coverage

Illinois Medicaid covers Vyleesi for premenopausal women with HSDD, subject to prior authorization. The PA process requires a clinical diagnosis documented using a validated tool (FSFI or FSDS-R), confirmation of acquired and generalized presentation, and documentation that mood or relationship etiologies have been assessed. [9] Approval timelines vary by managed care organization (MCO) but typically run 3 to 7 business days.

Commercial Insurance

Coverage varies widely. Many Illinois Blue Cross Blue Shield PPO plans require step therapy, meaning the patient may need to demonstrate that a trial of psychological intervention (such as 4 to 6 weeks of sex therapy or counseling) was attempted or was clinically inappropriate before Vyleesi is approved. United Healthcare and Aetna plans in Illinois have similar requirements. [11]

Cash Pay and Manufacturer Assistance

The Vyleesi list price runs approximately $1,000 per auto-injector. Palatin Technologies previously offered a savings program reducing cost to $99 for eligible commercially insured patients. Uninsured patients may qualify for patient assistance programs through the manufacturer. Compounded bremelanotide from a 503A pharmacy typically costs $150 to $350 per vial, depending on the pharmacy and quantity.

503A Compounding Pharmacies in Illinois

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies may prepare bremelanotide for individual patients when a prescriber writes a patient-specific order. [10] The Illinois Department of Financial and Professional Regulation oversees compounding pharmacies under the Illinois Pharmacy Practice Act (225 ILCS 85/). [4]

What "503A" Means for You

A 503A pharmacy compounds in response to a specific prescription, unlike a 503B outsourcing facility that manufactures in bulk. For bremelanotide, a 503A compound would be prepared as a subcutaneous injection using USP-grade active pharmaceutical ingredient (API). The pharmacist must follow USP Chapter 797 sterile compounding standards. [12]

Quality Considerations

The FDA has not approved any compounded version of bremelanotide, meaning potency, sterility, and stability guarantees rest entirely on the pharmacy's internal quality controls rather than on an NDA dossier. Ask any 503A pharmacy for their most recent USP 797 inspection report and sterility testing certificates before accepting a compounded product. [10]

Telehealth-Specific Guidance for Illinois Patients

Illinois Public Act 101-0528 mandates insurance parity for telehealth, meaning your insurer cannot deny coverage of a Vyleesi consultation solely because it was conducted via video rather than in-person. [6] The Illinois Telehealth Act also prohibits prescribers from requiring an in-person visit as a precondition for a telehealth prescription of non-controlled medications. Bremelanotide is not a federally scheduled controlled substance, so no Ryan Haight Act restrictions apply.

What to Prepare Before Your Online Visit

Have a blood pressure reading taken within 24 hours (home cuff, pharmacy kiosk, or urgent care). Complete the FSFI and FSDS-R questionnaires if sent as pre-visit forms. List all current medications, supplements, and herbal products, because alpha-melanocyte stimulating hormone analogs may interact with blood-pressure-raising agents including decongestants and stimulants. Have your insurance card ready for benefits verification.

Platform Selection

Choose a telehealth platform where the prescribing clinician holds an active Illinois medical or advanced practice license verifiable through IDFPR. [4] Platforms staffed by out-of-state clinicians without Illinois licensure cannot legally prescribe to Illinois residents.

Transferring a Vyleesi Prescription to Illinois

If you received a Vyleesi prescription from a provider in another state and have moved to or are visiting Illinois, you have two options.

First, the original prescriber can electronically transmit the prescription to an Illinois-licensed pharmacy if they hold a valid prescriber registration in Illinois (or if it was a federal DEA practitioner, though bremelanotide is not DEA-scheduled). Because bremelanotide is a legend drug rather than a controlled substance, pharmacy-to-pharmacy transfer is permitted under Illinois pharmacy law as long as the original prescription has remaining authorized refills. [13]

Second, you can establish care with a new Illinois provider, who will issue a fresh prescription after a clinical evaluation. This is typically faster than coordinating a transfer from an out-of-state prescriber who may not hold Illinois prescribing authority.

Typical Timeline from Consultation to First Dose

Most Illinois patients reach first injection within 5 to 14 days of their initial telehealth or in-person consultation. The table below reflects typical scenarios.

| Scenario | Estimated Days to First Dose | |---|---| | Cash-pay patient, specialty pharmacy | 3 to 6 days | | Commercial insurance, no PA needed | 4 to 8 days | | Commercial insurance, PA required | 8 to 18 days | | Illinois Medicaid with PA | 7 to 15 days | | 503A compounding pharmacy | 5 to 10 days |

Drug Interactions and Contraindications Relevant to Illinois Prescribers

The FDA label identifies naltrexone as a drug that may reduce bremelanotide's effectiveness due to opioid receptor competition. [1] Patients on naltrexone for alcohol use disorder or opioid use disorder should discuss this interaction explicitly. Indomethacin pharmacokinetics are also altered by bremelanotide co-administration, with bremelanotide reducing peak indomethacin concentrations by approximately 20%. [1]

Absolute contraindications per the FDA label include known cardiovascular disease, a history of uncontrolled hypertension, or high cardiovascular risk. [1] The American Heart Association defines high cardiovascular risk as a 10-year ASCVD risk above 10% using the Pooled Cohort Equations. [14] Illinois prescribers should calculate this score for patients over 40 before initiating bremelanotide.

The RECONNECT safety dataset found that blood-pressure-related adverse events led to discontinuation in 1.7% of the bremelanotide group versus 0.4% of the placebo group, underscoring that provider oversight is not optional. [2]

How Vyleesi Compares to Flibanserin (Addyi) for Illinois Patients

Both drugs treat HSDD in premenopausal women, but their mechanisms and administration differ substantially. Flibanserin is a daily oral tablet that modulates serotonin, dopamine, and norepinephrine. [15] Vyleesi is an as-needed subcutaneous injection taken 45 minutes before anticipated sexual activity.

Flibanserin carries a black-box warning against concurrent alcohol use and is DEA-scheduled as a non-scheduled legend drug with REMS requirements. [15] Vyleesi carries no REMS and no alcohol restriction, which some patients and prescribers find more practical. The RECONNECT trial did not directly compare the two agents, so head-to-head efficacy data do not exist. Prescribers typically choose between them based on patient preference for daily versus on-demand dosing, tolerability profiles, and formulary access. [2]

The International Society for the Study of Women's Sexual Health (ISSWSH) 2021 process-of-care pathway for HSDD lists both agents as first-line pharmacological options after non-pharmacological approaches have been considered or declined by the patient. [16]

Injection Technique and Storage for Home Use

Vyleesi comes as a single-dose auto-injector. The patient self-injects into the abdomen or thigh 45 minutes before sexual activity. The injector should be stored at room temperature (below 77°F / 25°C) and protected from light. [1] Unused injectors should not be frozen.

Patients new to self-injection typically benefit from a brief demonstration video or a live walk-through with a pharmacist or nurse at the time of dispensing. Illinois specialty pharmacies are required to provide counseling at first dispensing under the Illinois Pharmacy Practice Act. [4]

Common injection-site reactions include local bruising and transient erythema, reported in 17% of RECONNECT participants. [2] These reactions are self-limiting and do not require discontinuation in most cases.